DGAP-Adhoc

Biotest AG: Discussions regarding business combination - Seite 2

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,500 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

IR contact

Dr. Monika Buttkereit

phone: [phone]

email: [e-mail]

PR contact

Dirk Neumüller

phone: [phone]

email: [e-mail]


Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201

Preference shares: securities' ID No. 522723; ISIN DE0005227235

Listing: Prime Standard

Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich, Stuttgart

Contact:

Dr. Michael Ramroth

Chief Financial Officer

Biotest AG

Landsteinerstr. 3

63303 Dreieich

Tel. [phone]

Fax: [phone]

[e-mail]

---

29-March-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---

Language:	English
Company:	Biotest AG
	Landsteinerstraße 5
	63303 Dreieich
	Germany
Phone:	0 61 03 - 8 01-0
Fax:	0 61 03 - 8 01-150
E-mail:	[e-mail]
Internet:	http://www.biotest.de
ISIN:	DE0005227235, DE0005227201
WKN:	522723, 522720
Indices:	SDAX
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

End of Announcement	DGAP News Service

559903  29-March-2017 CET/CEST